What Peptides Are

The definition that matters

A peptide is a short chain of amino acids — conventionally 2 to about 50 residues — joined by peptide bonds. Longer chains fold into what we call proteins. That length distinction is not cosmetic: it determines how a molecule is absorbed, how quickly enzymes degrade it, whether it can be given orally, and how regulators classify it. Many compounds marketed as "peptides" are not peptides at all (HCG is a glycoprotein hormone; Danuglipron is a small molecule), and that mislabeling is one of the most common sources of confusion in consumer content.

Core terminology

• Agonist — binds a receptor and activates it (e.g. Semaglutide at the GLP-1 receptor).
• Antagonist — binds a receptor and blocks activation without triggering it.
• Secretagogue — stimulates the body's own release of a hormone rather than replacing it (e.g. Ipamorelin prompting endogenous growth hormone).
• Analogue — a structurally modified version of a natural peptide, usually altered to resist enzymatic breakdown or extend half-life.
• Half-life — the time for circulating concentration to fall by half; the single biggest driver of dosing frequency.
• Bioavailability — the fraction of an administered dose that reaches systemic circulation. Most peptides have near-zero oral bioavailability, which is why injection, intranasal, or specialized oral formulations dominate.
• Pulsatile vs. steady-state — some axes (growth hormone) are physiologically pulsatile, so timing matters as much as total dose.

Receptor classes you will encounter repeatedly

• Incretin receptors (GLP-1, GIP, glucagon) — metabolic and weight regulation.
• Growth hormone axis (GHRH receptor, ghrelin/GHS-R receptor) — secretagogues that drive endogenous GH release.
• Melanocortin receptors (MC1R–MC5R) — pigmentation, sexual function, inflammation.
• Neuropeptide and nootropic targets — often multiple or incompletely characterized mechanisms.
• Tissue-repair signaling — frequently non-receptor mediated or acting through growth factor and angiogenic pathways.

How to read a clinical study

• Check the design first. Randomized, double-blind, placebo-controlled trials outrank open-label studies, which outrank case series, which outrank animal and in-vitro work.
• Check the population. Results in diabetic adults do not automatically transfer to healthy athletes, and rodent findings frequently fail to replicate in humans.
• Check the endpoint. A statistically significant change in a biomarker is not the same as a clinically meaningful change in how someone feels or functions.
• Check the dose and route. A benefit shown with intravenous administration in a hospital says little about a subcutaneous home protocol.
• Check the sample size and duration. Small, short trials cannot detect uncommon harms.
• Check who funded it and whether the results were independently replicated.

Evidence tiers used across this library